Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure
Michele Emdin, Alberto Aimo, Vincenzo Castiglione, et al.
Journal of the American College of Cardiology (2020) Vol. 76, Iss. 15, pp. 1795-1807
Closed Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology
Julio Núñez, Rafael de la Espriella, Patrick Rossignol, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 10, pp. 1751-1766
Open Access | Times Cited: 91
Mechanisms and Prognosis of Intolerance to Angiotensin Receptor Neprilysin Inhibitors in Advanced Heart Failure: Insights from Vasodilator Challenge
Giulio Cacioli, Guglielmo Gallone, Alessandro Verde, et al.
Canadian Journal of Cardiology (2025)
Closed Access | Times Cited: 2
Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders
Arun Samidurai, Lei Xi, Anindita Das, et al.
The Annual Review of Pharmacology and Toxicology (2022) Vol. 63, Iss. 1, pp. 585-615
Open Access | Times Cited: 53
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
Arantxa González, Mark Richards, Rudolf A. de Boer, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 6, pp. 927-943
Open Access | Times Cited: 50
Sex-Based Differences in Heart Failure
Sadiya S. Khan, Lauren B. Beach, Clyde W. Yancy
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 15, pp. 1530-1541
Open Access | Times Cited: 43
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines
Hiroyuki Tsutsui
Pharmacology & Therapeutics (2022) Vol. 238, pp. 108185-108185
Open Access | Times Cited: 32
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial
Michele Senni, Wendimagegn Alemayehu, David Sim, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 9, pp. 1614-1622
Open Access | Times Cited: 29
From nitrate to NO: potential effects of nitrate-reducing bacteria on systemic health and disease
Hongyu Liu, Yisheng Huang, Mingshu Huang, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 17
Sex Differences and Regulatory Actions of Estrogen in Cardiovascular System
Kazutaka Ueda, Nobuaki Fukuma, Yusuke Adachi, et al.
Frontiers in Physiology (2021) Vol. 12
Open Access | Times Cited: 35
Vericiguat for Heart Failure with Reduced Ejection Fraction
Carlo Lombardi, Giuliana Cimino, Matteo Pagnesi, et al.
Current Cardiology Reports (2021) Vol. 23, Iss. 10
Open Access | Times Cited: 32
Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines
Antoni Bayés‐Genís, Alberto Aimo, Marco Metra, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 6, pp. 916-926
Open Access | Times Cited: 24
Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications
Francesca Vannuccini, Alessandro Campora, Maria Barilli, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2471-2471
Open Access | Times Cited: 22
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
Vincenzo Castiglione, Francesco Gentile, Nicolò Ghionzoli, et al.
Cardiac failure review (2023) Vol. 9
Open Access | Times Cited: 15
Vericiguat improves cardiac remodelling and function in rats with doxorubicin‐induced cardiomyopathy
Wen Chen, Ying Wu, Jian Li, et al.
ESC Heart Failure (2025)
Open Access
Worsening heart failure: progress, pitfalls, and perspectives
Fonseca Cândida, Baptista Rui, Franco Fátima, et al.
Heart Failure Reviews (2025)
Open Access
Relationship between Systolic Ejection Time and Inflammation in End-Stage Heart Failure
Joel Gutovitz, Jerry Kutcher, David Z. Cherney, et al.
Southern Medical Journal (2025) Vol. 118, Iss. 3, pp. 167-170
Closed Access
Eligibility of Outpatients with Chronic Heart Failure for Vericiguat and Omecamtiv Mecarbil: From Clinical Trials to the Real-World Practice
Paolo Basile, Alessio Falagario, Maria Cristina Carella, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1951-1951
Open Access
Longitudinal changes in circulating cyclic guanosine monophosphate in women over the menopause transition compared to men: the Coronary Artery Risk Development in Young Adults (CARDIA) study
Giuliana Lee, Wendy Ying, Bharath Ambale‐Venkatesh, et al.
Menopause The Journal of The North American Menopause Society (2025)
Closed Access
Similarities and Differences Between HFmrEF and HFpEF
Peixin Li, Hengli Zhao, Jianyu Zhang, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 30
Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF
Antje Schauer, Volker Adams, Antje Augstein, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3570-3570
Open Access | Times Cited: 28
Recent advances in pharmacological treatment of heart failure
Massimo Iacoviello, Alberto Palazzuoli, Edoardo Gronda
European Journal of Clinical Investigation (2021) Vol. 51, Iss. 11
Open Access | Times Cited: 27
Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations
Hayah Kassis‐George, Nathan J. Verlinden, Sheng Fu, et al.
Therapeutics and Clinical Risk Management (2022) Vol. Volume 18, pp. 315-322
Open Access | Times Cited: 18
Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events
Vishal N. Rao, Javier Dı́ez, Finn Gustafsson, et al.
Journal of Cardiac Failure (2022) Vol. 29, Iss. 3, pp. 389-402
Open Access | Times Cited: 17
Comparative efficacy of vericiguat to sacubitril/valsartan for patients with heart failure reduced ejection fraction: Systematic review and network meta-analysis
Dong-Won Kang, Seung‐Ho Kang, Kyungmin Lee, et al.
International Journal of Cardiology (2024) Vol. 400, pp. 131786-131786
Closed Access | Times Cited: 3
Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling
Julia Rüdebusch, Alexander Benkner, Neetika Nath, et al.
British Journal of Pharmacology (2020) Vol. 179, Iss. 11, pp. 2430-2442
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top